Kadence Bio’s Post

📢 World Leaders Discuss Europe's Cluster Policy for Green Digital and Biotech Transitions 💥 More than 900 experts from clusters and the EU Commission gathered in Brussels for the European Cluster Conference. They discussed cluster policy needed for Europe to become a world leader in green and digital transitions and biotechnology. 🌍💪🏼 Compared to the US and China, EU biotech clusters lack support in funding, resources, and scaling up bioproduction. The European Federation of Pharmaceutical Industries and Associations suggested focusing resources in a few large clusters. However, some experts emphasized the importance of networking and mapping existing expertise in topic-specific metaclusters. 🌐🔬 Jan-Philippe Kramer, from the European Cluster Collaboration Platform, presented Innovation scores, showing that China has caught up with the EU in terms of innovation. Clusters play a crucial role in the innovation process, but their sector-specific needs must be better understood and heard. 👩💼💻💡 #BioprocessUpdates #EuropeanClusterConference #clusterpolicy #greentransitions #digitaltransitions #biotechnology #EUbiotechclusters #funding #resources #scalingup #bioproduction #networking #metaclusters #innovation #sectorspecific #EU ▷ Read the full article here: 📎 https://lnkd.in/d6qjD5ce

🌟 BIOCHINA 25 is just around the corner! 🧬 BIOCHINA is China's premier bio-convention with over 3,000 biotech companies from around the world. This year’s event promises to be a game-changer for the biotech industry. I’m excited to connect with like-minded professionals at BIOCHINA 25 to explore potential partnerships, licensing deals, and funding opportunities. Let’s discuss how we can collaborate to drive innovation and growth in the biotech sector. 👉 Who’s attending BIOCHINA 25? Let’s connect and chat! 🤝 #BIOCHINA25 #biotech #innovation #partnership #funding

𝐓𝐫𝐚𝐝𝐞 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐭𝐨 𝐍𝐨𝐫𝐭𝐡 𝐂𝐚𝐫𝐨𝐥𝐢𝐧𝐚 🚀 Last week, our colleague Alejandro R. was on a trade mission to #NorthCarolina, between meetings, visits, and talks of great interest. North Carolina is one of the most important #biotechnology centers in the USA, home to a dense concentration of #biotech companies, pharmaceutical #research, academic institutions and #innovation centers. This mission opens interesting doors for #GalicianBiotechnology: Forging strategic partnerships between researchers and creating new services to improve our market-oriented R&D capabilities, strategies to help Galician biotech startups to smoothly enter the US market or a possible cooperation aimed at positioning #Galicia as a key player in the biotech sector are some of the milestones achieved. We were accompanied by 7 other entities from the Galician bioregion, in collaboration with the Axencia Galega de Innovación. Undoubtedly, it is an excellent opportunity to meet the leaders of the biotech sector in the area and explore opportunities for collaboration. The mission was clear: to position Galicia as a leader in the global biotech ecosystem, creating opportunities for talent, research, and business growth. #ProgramaFoexga #FEDER

US House Passes Bill to Blacklist Some China Biotech Firms China hawks in the US House overcame a last-ditch lobbying effort and passed legislation, dubbed the Biosecure Act, that would blacklist Chinese biotech companies and their US subsidiaries. The bill, approved by a vote of 306 to 81, now goes to the Senate. At stake, the bill’s backers argued, is whether China will dominate another field the US pioneered, amid fears China could engineer bioweapons or otherwise capitalize on biological data vacuumed up from the rest of the world. The legislation which passed the House Oversight Committee 40-1 in May, would affect five companies to start: BGI Group, BGI spinoffs MGI Tech and MGI’s US subsidiary Complete Genomics, WuXi AppTec, and WuXi Biologics. https://lnkd.in/g-t8Ng7v #aspenalert #biotech #bioprocess

🌏 How Chinese Biopharma is Reshaping Global Biotech – What This Means for Australia  The innovation landscape in biotechnology is shifting, amidst rise in geopolitical tensions and ever-increasing healthcare-related spending. In our upcoming event, we are excited to collaborate with Dr. Dirk van der Kley from The Australian National University's Crawford School of Public Policy to explore what Australia can learn from global trends in biotechnology innovation and competitiveness. In his recent article, Dirk draws upon data from key data points including publications, clinical trial activity, and US FDA approvals to underscore the rapid emergence and growth of China’s innovative biopharma sector. Historically, China’s biotechnology industry has focused on upstream ingredient manufacturing, generics production, contract manufacturing and contract research. However, homegrown Chinese drug developers moving quickly and investing in innovation to challenge industry incumbents and break into global markets, especially in US. For Australia, these developments underscore both the opportunities and challenges of positioning ourselves as a leader in biotech amidst global competition. Join us for a unique discussion with industry experts and leaders including Dirk as we navigate the future of Australian biotech through a global lens. 📅 December 4th 12-4PM AEDT 📍 Virtual & in-person (Melbourne) 🔗 RSVP: https://lu.ma/qblain9u Looking forward to connecting with you! Event Supporters: Australia China Business Council Australia China Alumni Association ACASE #Biotech #Innovation #Australia #Pharma #FutureOfBiotech

Impressive line up of CEOs, largest since Covid hit. Taken together, topics raised paint a good picture of where China is when it comes to access to innovation. Of note is the fact that some sort of reform is being considered that would better promote access to innovation. This is needed not just by MNCs, but critically as well by emerging Chinese biotechs. #china #MNC #biopharma #biotech

Interestingly enough, despite industry-wide downturns, the Chinese #biotech sector shows signs of robust #innovation and strategic adaptability. In summary: 1. Innovation Through Outlicensing Deals originating from #China are surprisingly outpacing in-licensing, marking a significant shift towards unique, innovative biotech developments. 2. #Geopolitics Amidst geopolitical tensions, the resilience and strategic shifts in the Chinese biotech landscape are more crucial than ever. 3. Strategic Adaptations • Early-Stage Deals: To generate reliable data recognized globally, there is an increasing trend towards early-stage #outlicensing. • Chinese Discount: Current market conditions have led to more competitive pricing from Chinese biotech firms, making it an opportune time for global stakeholders to engage. All in all, it will be thrilling to watch the Chinese biotech sector navigate these challenges over the next 1-2 years. https://lnkd.in/e5a4tQu3

🎉 A Milestone Collaboration 🤝 We are incredibly proud to have witnessed the signing of the MOU between IPACE - IP Commercialize and Nerve Bioscience, marking the beginning of a strong and promising partnership. As a key player in this momentous occasion, we are excited to see how this collaboration will unfold and bring fresh innovations to both the South Korean and Thai markets. Nerve Bioscience, with its deep expertise in the bio-products industry, is a true leader in advancing technologies that span cosmetics, functional health foods, and pharmaceuticals. This partnership will surely unlock new opportunities for all involved, driving cross-border collaboration and business growth. At DeltaTech-Korea, we look forward to supporting this venture and playing an active role in bridging markets and enabling success. Here's to many more milestones ahead! 🌏🚀 #Partnership #Innovation #BioScience #GlobalCollaboration #SouthKorea #Thailand #Technology #BusinessExpansion #GrowthOpportunities

https://lnkd.in/eu957Fhr Our founder Leon 'Jun' T. participated in a KOL call with Li Watsek and Eric Schmidt from Cantor Fitzgerald today to discuss the trends in the current #dealmaking involving #ChinaInnovation. Watch the replay on #BioVerse #YouTubeChannel here: https://lnkd.in/eu957Fhr Here are the key #takeways of the event: 📢 Top three trends in 2024. 1) Diversification of modalities and disease areas. Before 2023, most deals were focused on I/O in oncology. This year, we have seen a lot of #ADC, #TCE for #AutoimmuneDiseases, and small molecules. 2) A focus on biologics, such as PD1/VEGF, ADCs, and radiopharmaceuticals, which largely overlap with the U.S. interest. The gap of U.S. and China is closing. 3) Earlier stage of assets. Curon Biopharmaceutical/Merck, Chimagen Biosciences/GSK deals were all Ph1. Some deals only dosed 1 or 2 patients, which did not happen prior to 2023. 📢 Big pharma's pending #PatentCliff, poor capital markets in China, and a shift in mindset are driving forces behind the uptick in cross-border BD activities. Capital decoupling has resulted in a precipitation of U.S.-based VC funds, due to geopolitical risk. Price control (5% net price of U.S. branded drugs) in China also shuts the path for a sustainable biopharma business model. These led to a greater willingness on the part of China biotechs to seek partners in the West, and selling their best assets. 📢 The innovation foundation is strong in China. China has come a long way to narrow the R&D gap with the West. Summit Therapeutics, Inc./Akeso Biopharma story may not be a one-hit wonder. Underpinning the innovative engine is the massive talent pool (greatest number of STEM-educated PhDs/postdocs in the world), low development cost, and world-class chemistry/protein engineering capabilities. 📢 ADCs, TCEs, and obesity assets are on top of the shopping list. Oncology, immunology, and obesity are top areas of interest. VC funds are scouting for assets that big pharma will buy in 2-3 years. Deals in radiopharma are unlikely to come out of China, as the "process is the product", which is challenging to transfer. 📢 #Newco model is gaining traction. Housing Chinese assets in a U.S.-based company with U.S. investors solves several problems, including quality assets, quality mgmt. team, capital table, and cultural mismatch. Candid Therapeutics and Hengrui Pharma Co.,Ltd/Kailera Therapeutics are two success stories. 📢 Geopolitical risks and outlook for BD activity in 2025. The Biosecure Act risk is real, and we do not know if this will be expanded under the new administration. The CDMO space is undergoing decoupling. While there might be some uncertainty on the U.S.-China geopolitical front, EU pharma and China BD transaction is unencumbered. If the U.S. wants to stay competitive, the access to China innovation may be a necessity.

analytica Vietnam 2025 Set to Be the Biggest Yet with 85% of Exhibition Halls Sold Out! The 8th edition of analytica Vietnam 2025, scheduled to take place from April 2-4, 2025, at the Saigon Exhibition and Convention Center (SECC) in Ho Chi Minh City, will bring together leading experts, researchers, and professionals from around the world. With an impressive 85% of exhibition space booked nine months ahead and past exhibitors increasing their booth sizes compared to the 2023 edition, the upcoming event promises to be the biggest and most successful yet. Highlights of analytic Vietnam 2025: A 30% increase in exhibition space, featuring over 300 exhibitors and brands, is set to attract more than 6,000 attendees. Focus topics on Laboratory Technology, Sustainability, Artificial Intelligence, and Digitalization, which will be focal points of discussion throughout the show. Exciting New Additions: Debut of the Startup Pavilion, Lab Design & Construction Section, Innovation Zone, and Lab Pavilion. Read more about analytic Vietnam 2025 news in Guidechem: https://lnkd.in/etKqZeJC #guidechem #analyticavietnam #analyticaVietnam2025 #analytica #analysis #laboratorytechnology #biotechnology #chemistry #vietnam #vietnamexhibition #pharma #pharmaceutical #diagnostics #lifescience #foodtechnology #laboratory #laboratoryequipment #technology